Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07264790 · ClinicalTrials.gov registry record · Phase 1

Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon

A Phase 1 study, sponsored by Duke University.

Recruiting
Registry status
Phase 1
Development phase
25
Enrollment target

NCT07264790: Recruiting Phase 1 study, sponsored by Duke University.

NCT07264790 is a Phase 1 study that is actively recruiting participants, run by Duke University. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07264790, a Phase 1 study, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
Phase 1
Development phase
25 participants
Enrollment target

Study Summary

The purpose of the study is to determine whether pharmacologic delay using minoxidil in patients undergoing bilateral risk reducing mastectomy with reconstruction could achieve improvement in flap perfusion and flap viability at the time of surgery. Patients will undergo randomization of their breasts to determine which breast will receive the experimental intervention and which breast will serve as the internal control (receive placebo). The experimental breast will receive the novel pharmacologic delay treatment, 5% minoxidil, while the internal control breast will receive the current standard of care, which does not include any topical application prior to surgery - a placebo control will be used. This will be a triple-blind study, where both the participants and investigators will be blinded to which breast will receive the intervention. The patients will receive two bottles "compound A" and "compound B" with directions from the pharmacy for which compound to apply to each breast. Product will be applied for 2 weeks prior to planned surgery. Surgery will proceed without any changes to standard practice.

Primary Outcome

Rate of study participation from eligible patients undergoing bilateral risk-reducing mastectomy with tissue expander-based implant reconstruction

Interventions

  • DRUG Minoxidil
  • DRUG Hair mousse

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2026-03-16
Est. Completion 2027-09
Phase Phase 1
Duke University

1,725 total trials

What NCT07264790 shows while recruiting

NCT07264790 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 2 interventions - of which Minoxidil is the first listed.

NCT07264790 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07264790 about?

NCT07264790 is a clinical study titled "Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon". The purpose of the study is to determine whether pharmacologic delay using minoxidil in patients undergoing bilateral risk reducing mastectomy with reconstruction could achieve improvement in flap perfusion and flap viability at the time of surgery. Patients will undergo randomization of their breas...

What is the current status of trial NCT07264790?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2026-03-16. Estimated completion is 2027-09.

What interventions are being tested in trial NCT07264790?

The interventions under investigation include: Minoxidil (DRUG), Hair mousse (DRUG).

Who is sponsoring clinical trial NCT07264790?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07264790's enrollment target sits among peer trials

25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01166854 · 25 participants

    Characterization of Familial Myopathy and Paget Disease of Bone

  • NCT01913106 · 25 participants · Phase 1

    HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

  • NCT02138669 · 25 participants · NA

    Intacs Prescription Inserts for Keratoconus Patients

  • NCT02174549 · 25 participants · Phase 1

    Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07264790, the US trial registry maintained by the National Library of Medicine. NCT07264790 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.